Company
Technology
Team
Board of Directors
Management
Extended Management
Partners & Advisors
Preclinical Research
Clinical Research
Strategic Investment
Investors
News
Contact
6 August 2021
Le Temps is reporting about CHF 7.2 million of seed funding raised for the development of RocketVax’s SARS-CoV-2 vaccine
“Founded in 2020, Basel-based company RocketVax has just secured funding to launch the pre-clinical phase of its Covid-19 vaccine development”.
PREVIOUS NEWS
NEXT NEWS
SHARE THIS NEWS